arrow
T

Thomas Walter

Department of Oncology
H指数:54
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort

对纤维层状癌的全身性治疗反应与生存:一项法国AGEO-SFCE多中心回顾性队列研究

2025-05-010
OAAI
PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis

PRRT联合钬-166-SIRT(HEPAR PLuS)与仅PRRT在转移性神经内分泌肿瘤患者中的比较:一项倾向性评分匹配分析

2025-04-290
OAAI
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025-04-040
OAAI
Comprehensive molecular portrait reveals genetic diversity and distinct molecular subtypes of small intestinal neuroendocrine tumors

综合分子图谱揭示了小肠神经内分泌肿瘤的遗传多样性和独特的分子亚型

2025-03-040
OA
Survival of patients managed in France for duodenal neuroendocrine tumors (D-NET): a 20-year multicenter cohort study from the GTE group: a cohort study
2024-07-010
OAAI
Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project
2024-06-011
OAAI
Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force
2024-05-163
PRE
Beyond MEN1, When to Think About MEN4? Retrospective Study on 5600 Patients in the French Population and Literature Review
2024-01-3011
OA
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
2024-01-113
OA